Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981

Last updated: April 10, 2026
Sponsor: Chong Kun Dang Pharmaceutical
Overall Status: Completed

Phase

2

Condition

Knee Injuries

Osteoarthritis

Treatment

CKD-981(2)

Reference Drug

Placebo Drug

Clinical Study ID

NCT06954766
A145_01OA2401
  • Ages 40-80
  • All Genders

Study Summary

The purpose of this study is to prove that the temporary symptom improvement effect on knee osteoarthritis using CKD-981

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients between 40 years and 80 years old

  • Patients who have experiencing knee pain more than 8 weeks

  • VAS more than 40 mm

  • Kellgren and Lawrence grade 2 and 3 in X' ray knee joint

Exclusion

Exclusion Criteria:

  • Previous knee surgery in affected side

  • Patients with Rheumatoid arthritis, connective tissue disease, Paget's disease

  • Infection of knee joint

  • BMI more than 35kg/m2

Study Design

Total Participants: 100
Treatment Group(s): 7
Primary Treatment: CKD-981(2)
Phase: 2
Study Start date:
April 28, 2025
Estimated Completion Date:
October 28, 2025

Study Description

The aim of this pilot study is to evaluate the efficacy and safety of CKD-981 in patients with mild to moderate degenerative knee osteoarthritis who have been experiencing pain more than 8 weeks

Connect with a study center

  • Wonju Severance Christian Hospital

    Wonju,
    Korea, Republic of

    Site Not Available

  • Wonju Severance Christian Hospital

    Wŏnju,
    South Korea

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.